JP2022547711A - ナルコレプシーの治療に使用するためのｔａｋ－９２５ - Google Patents

ナルコレプシーの治療に使用するためのｔａｋ－９２５ Download PDF

Info

Publication number
JP2022547711A
JP2022547711A JP2022516270A JP2022516270A JP2022547711A JP 2022547711 A JP2022547711 A JP 2022547711A JP 2022516270 A JP2022516270 A JP 2022516270A JP 2022516270 A JP2022516270 A JP 2022516270A JP 2022547711 A JP2022547711 A JP 2022547711A
Authority
JP
Japan
Prior art keywords
compound
subject
administration
methyl
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547711A5 (https=
Inventor
ハートマン、デボラ
エヴァンス、レベッカ
ファエッセル、ヘレーネ
慎一郎 田中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022547711A publication Critical patent/JP2022547711A/ja
Publication of JP2022547711A5 publication Critical patent/JP2022547711A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022516270A 2019-09-13 2020-09-12 ナルコレプシーの治療に使用するためのｔａｋ－９２５ Pending JP2022547711A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900298P 2019-09-13 2019-09-13
US62/900,298 2019-09-13
US202063031686P 2020-05-29 2020-05-29
US63/031,686 2020-05-29
PCT/IB2020/058483 WO2021048822A1 (en) 2019-09-13 2020-09-12 Tak-925 for use in treating narcolepsy

Publications (2)

Publication Number Publication Date
JP2022547711A true JP2022547711A (ja) 2022-11-15
JP2022547711A5 JP2022547711A5 (https=) 2023-09-20

Family

ID=72560858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516270A Pending JP2022547711A (ja) 2019-09-13 2020-09-12 ナルコレプシーの治療に使用するためのｔａｋ－９２５

Country Status (11)

Country Link
US (1) US20220339143A1 (https=)
EP (1) EP4028004A1 (https=)
JP (1) JP2022547711A (https=)
KR (1) KR20220062012A (https=)
CN (1) CN114980892A (https=)
AU (1) AU2020346456A1 (https=)
BR (1) BR112022004587A2 (https=)
CA (1) CA3154321A1 (https=)
CO (1) CO2022004596A2 (https=)
MX (1) MX2022003018A (https=)
WO (1) WO2021048822A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022004576A2 (pt) * 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica
MX2022008392A (es) 2020-01-10 2022-08-08 Takeda Pharmaceuticals Co Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
BR112023020104A2 (pt) * 2021-04-02 2023-11-14 Takeda Pharmaceuticals Co Métodos para recuperação pós-operação, para facilitar a recuperação ou reduzir o tempo de recuperação da anestesia, para prevenir ou tratar distúrbios/depressão respiratória pós-operatória ou distúrbios/depressão respiratória induzida por opioides, sedação pós-operatória ou sedação induzida por opioides e para reduzir um efeito colateral de opioides
CN119677753A (zh) 2022-04-22 2025-03-21 帝人制药株式会社 氧杂氮杂环庚三烯衍生物
AR130709A1 (es) 2022-10-07 2025-01-08 Kissei Pharmaceutical Compuesto de ciclopentano
WO2024095158A1 (en) * 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
TW202535890A (zh) 2023-10-20 2025-09-16 日商帝人製藥股份有限公司 氧氮呯衍生物之結晶或其溶劑合物之結晶
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
WO2025229493A1 (en) * 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
ES2843952T3 (es) * 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
US10022355B2 (en) * 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途

Also Published As

Publication number Publication date
BR112022004587A2 (pt) 2022-06-14
KR20220062012A (ko) 2022-05-13
CN114980892A (zh) 2022-08-30
US20220339143A1 (en) 2022-10-27
WO2021048822A1 (en) 2021-03-18
CO2022004596A2 (es) 2022-08-30
AU2020346456A1 (en) 2022-04-14
CA3154321A1 (en) 2021-03-18
EP4028004A1 (en) 2022-07-20
MX2022003018A (es) 2022-06-14

Similar Documents

Publication Publication Date Title
JP2022547711A (ja) ナルコレプシーの治療に使用するためのｔａｋ－９２５
JP2022547604A (ja) 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用
TWI293250B (en) Use of optically pure (s,s)-reboxetine in the manufacture of a medicament for the treatment or prevention of migraine headaches
Van Gastel Drug-induced insomnia and excessive sleepiness
JP2025510294A (ja) 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2025510916A (ja) 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2022547604A5 (https=)
JP2026505779A (ja) 授乳期の母親における精神障害の処置に使用するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
Van Gastel Drug-induced insomnia and excessive sleepiness
JP2026505780A (ja) 精神障害の処置
US20020183306A1 (en) Combination treatment for sleep disorders including sleep apnea
Thase et al. Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review
CN1541092A (zh) 治疗原发性失眠的方法
JP2024511676A (ja) 術後回復のためのオレキシン２受容体アゴニストの使用
TW202302100A (zh) 食慾激素２受體促效劑於治療食慾激素介導之疾病或病症之用途
JP2025510911A (ja) 精神障害の治療
JP2010513227A (ja) 覚醒を促進するためのＩｈチャネル阻害剤
US20250375409A1 (en) Treatment of REM Behavior Disorder
CN118401239A (zh) 用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮
Downer PALLIATIVE CARE CASE OF THE MONTH
EP2269600A1 (en) Treatment of sleep disorders using eplivanserin in COPD patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250128